Verrica Pharmaceuticals Inc (VRCA)

$5.95 +0.22 (3.84%)
Market Cap 98.44M
Revenue (ttm) 35.58M
Net Income (ttm) -17.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -50.28%
Debt to Equity Ratio 0.00
Volume 25,060
Avg Vol 74,450
Day's Range N/A - N/A
Shares Out 17.18M
Stochastic %K 11%
Beta 1.49
Analysts Strong Sell
Price Target $15.60

Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 453 3300
Address:
44 West Gay Street, Suite 400, West Chester, United States
arturogf
arturogf Jun. 11 at 4:38 PM
My take on $VRCA https://www.tradingview.com/chart/VRCA/oIzCS3aM-Clear-accumulation-for-VRCA/?social_toast=true
0 · Reply
DARKP00L
DARKP00L May. 26 at 11:27 AM
$VRCA 06:51 on May. 26 2026 HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12 #tradeideas
0 · Reply
Bbboston
Bbboston May. 23 at 2:12 PM
$VRCA Yes 315 could be a huge money maker, but if YCANTH shows to be effective for common warts, that could be huge as well.
0 · Reply
t_lamp3
t_lamp3 May. 13 at 8:44 PM
$VRCA Everyone’s focused on YCANTH revenue… meanwhile the real lottery ticket is VP-315. A potential injectable alternative to cutting basal cell carcinomas off. Phase 2 showed: • 51% complete histologic clearance • 97% response rate • Minimal systemic exposure If Phase 3 hits, this isn’t just another derm company anymore. Feels like the market still thinks VRCA is a molluscum-only story. https://verrica.com/press_release/verrica-pharmaceuticals-presents-new-data-on-vp-315-from-its-phase-2-clinical-trial-in-basal-cell-carcinoma-at-the-40th-society-for-immunotherapy-of-cancer-annual-meeting/
0 · Reply
phd101
phd101 May. 13 at 5:29 PM
$VRCA strong rev growth
1 · Reply
MarketBeat
MarketBeat May. 13 at 3:09 AM
https://marketbeat.com/a/8651239/ $VRCA Verrica Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript
0 · Reply
BioGem
BioGem May. 12 at 9:29 PM
$VRCA I have mentioned their dismal performance for the past 6 months, and not sure why investors still bought it, all while they diluted by double the number of shares not too long ago. -Adoption of the product in the USA is too weak and slow, despite a big expansion in their sales team. -Their losses are deepening. -Cash burn is too heavy and unsustainable. -Cash is already critically low. -Add several millions in pre-funded warrant already vested. -I expect another round of dilution imminently.
0 · Reply
Merlintrader
Merlintrader May. 12 at 8:21 PM
$VRCA Verrica Pharmaceuticals (Nasdaq: $VRCA): Q1 2026 earnings show stronger YCANTH demand, lower debt burden and a still-tight cash clock https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 8:12 PM
$VRCA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.45 up 55.00% YoY • Reported revenue of $5.02M up 46.06% YoY
0 · Reply
Latest News on VRCA
Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:05 AM EDT - 11 days ago

Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026, 8:05 AM EDT - 18 days ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright

2026-05-26T10:19:56.000Z - 20 days ago

Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright

Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 1:30 PM EDT - 27 days ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026, 8:00 AM EDT - 4 weeks ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)

2026-05-12T21:57:53.000Z - 4 weeks ago

Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026

Verrica Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Verrica Pharmaceuticals Earnings release: Q1 2026

Verrica Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Verrica Pharmaceuticals Quarterly report: Q1 2026

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

May 12, 2026, 4:01 PM EDT - 4 weeks ago

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

May 5, 2026, 4:05 PM EDT - 5 weeks ago

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

SID

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

May 5, 2026, 8:00 AM EDT - 5 weeks ago

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

Verrica Pharmaceuticals Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Verrica Pharmaceuticals Proxy statement: Proxy filing

Verrica Pharmaceuticals Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Verrica Pharmaceuticals Proxy statement: Proxy filing

Verrica Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 3:00 PM EDT - 2 months ago

Verrica Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Apr 9, 2026, 4:05 PM EDT - 2 months ago

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Verrica Pharmaceuticals Slides: Corporate presentation

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 3 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025

Verrica Pharmaceuticals Annual report: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 3 months ago

Verrica Pharmaceuticals Annual report: Q4 2025

Verrica Pharmaceuticals Earnings release: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 3 months ago

Verrica Pharmaceuticals Earnings release: Q4 2025

Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)

2026-03-11T12:06:44.000Z - 3 months ago

Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 11, 2026, 8:00 AM EDT - 3 months ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Mar 5, 2026, 8:00 AM EST - 3 months ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Verrica Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 3 months ago

Verrica Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 4 months ago

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer

2026-02-12T13:11:17.000Z - 4 months ago

Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

Feb 12, 2026, 8:00 AM EST - 4 months ago

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan

2026-02-09T13:20:47.000Z - 4 months ago

Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Feb 9, 2026, 8:00 AM EST - 4 months ago

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Verrica Pharmaceuticals Slides: Investor presentation

Jan 9, 2026, 7:00 AM EST - 5 months ago

Verrica Pharmaceuticals Slides: Investor presentation

Verrica announces first patient dosed in program evaluating YCANTH

2026-01-07T13:16:25.000Z - 5 months ago

Verrica announces first patient dosed in program evaluating YCANTH

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Jan 7, 2026, 8:00 AM EST - 5 months ago

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline

2025-12-18T02:10:17.000Z - 6 months ago

Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline

Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders

2025-12-15T21:25:42.000Z - 6 months ago

Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders

Verrica Pharmaceuticals Registration statement: Registration Filing

Dec 15, 2025, 7:00 AM EST - 6 months ago

Verrica Pharmaceuticals Registration statement: Registration Filing

Verrica Pharmaceuticals announces private placement financing of $50M

2025-11-24T13:11:05.000Z - 7 months ago

Verrica Pharmaceuticals announces private placement financing of $50M

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Nov 24, 2025, 8:00 AM EST - 7 months ago

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Verrica Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 7 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q3 2025

Verrica Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 7 months ago

Verrica Pharmaceuticals Earnings release: Q3 2025

Verrica Pharmaceuticals Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 7 months ago

Verrica Pharmaceuticals Quarterly report: Q3 2025

Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)

2025-11-14T21:10:36.000Z - 7 months ago

Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:05 PM EST - 7 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Verrica Pharmaceuticals presents new data on VP-315 from Phase 2 trial

2025-11-10T13:15:34.000Z - 7 months ago

Verrica Pharmaceuticals presents new data on VP-315 from Phase 2 trial

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Nov 10, 2025, 8:00 AM EST - 7 months ago

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Verrica Pharmaceuticals initiated with a Buy at Lucid Capital

2025-11-05T11:46:01.000Z - 7 months ago

Verrica Pharmaceuticals initiated with a Buy at Lucid Capital

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 24, 2025, 11:00 AM EDT - 8 months ago

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

2025-10-20T20:45:12.000Z - 8 months ago

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Oct 20, 2025, 4:05 PM EDT - 8 months ago

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 7, 2025, 4:05 PM EDT - 8 months ago

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Verrica Pharmaceuticals development partner receives approval for YCANTH

2025-09-19T12:05:32.000Z - 9 months ago

Verrica Pharmaceuticals development partner receives approval for YCANTH

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Sep 19, 2025, 8:00 AM EDT - 9 months ago

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:30 AM EDT - 10 months ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 10 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2025

Verrica Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Verrica Pharmaceuticals Quarterly report: Q2 2025

Verrica Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Verrica Pharmaceuticals Earnings release: Q2 2025

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:01 PM EDT - 10 months ago

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Verrica reports 13,434 YCANTH dispensed applicator units in Q2

2025-07-09T11:15:25.000Z - 1 year ago

Verrica reports 13,434 YCANTH dispensed applicator units in Q2

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

Verrica announces amendment to collab, license agreement with Torri

2025-07-01T11:16:21.000Z - 1 year ago

Verrica announces amendment to collab, license agreement with Torri

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2025

Verrica Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q1 2025

Verrica Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q1 2025

Verrica Pharmaceuticals reports Q1 EPS (10c), consensus (14c)

2025-05-13T20:18:39.000Z - 1 year ago

Verrica Pharmaceuticals reports Q1 EPS (10c), consensus (14c)

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Verrica Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 3:00 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing

Verrica Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 1:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

2025-04-07T12:15:57.000Z - 1 year ago

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2024

Verrica Pharmaceuticals Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Annual report: Q4 2024

Verrica Pharmaceuticals Earnings release: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q4 2024

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Verrica Pharmaceuticals Registration statement: Registration Filing

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Registration statement: Registration Filing

Verrica Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

Verrica Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Mar 3, 2025, 7:00 AM EST - 1 year ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Feb 25, 2025, 4:05 PM EST - 1 year ago

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2024, 4:15 PM EST - 1 year ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Dec 6, 2024, 8:00 AM EST - 1 year ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Announces Pricing of $42.0 Million Public Offering

Nov 21, 2024, 7:30 AM EST - 1 year ago

Verrica Announces Pricing of $42.0 Million Public Offering

Verrica Announces Proposed Public Offering

Nov 20, 2024, 4:05 PM EST - 1 year ago

Verrica Announces Proposed Public Offering

Verrica Pharmaceuticals Quarterly report: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q3 2024

Verrica Pharmaceuticals Earnings release: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Verrica Pharmaceuticals Earnings release: Q3 2024

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Oct 11, 2024, 5:21 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Sep 27, 2024, 10:29 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Verrica Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 1:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2024

Verrica Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q2 2024

Verrica Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q2 2024

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 7:45 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

arturogf
arturogf Jun. 11 at 4:38 PM
My take on $VRCA https://www.tradingview.com/chart/VRCA/oIzCS3aM-Clear-accumulation-for-VRCA/?social_toast=true
0 · Reply
DARKP00L
DARKP00L May. 26 at 11:27 AM
$VRCA 06:51 on May. 26 2026 HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12 #tradeideas
0 · Reply
Bbboston
Bbboston May. 23 at 2:12 PM
$VRCA Yes 315 could be a huge money maker, but if YCANTH shows to be effective for common warts, that could be huge as well.
0 · Reply
t_lamp3
t_lamp3 May. 13 at 8:44 PM
$VRCA Everyone’s focused on YCANTH revenue… meanwhile the real lottery ticket is VP-315. A potential injectable alternative to cutting basal cell carcinomas off. Phase 2 showed: • 51% complete histologic clearance • 97% response rate • Minimal systemic exposure If Phase 3 hits, this isn’t just another derm company anymore. Feels like the market still thinks VRCA is a molluscum-only story. https://verrica.com/press_release/verrica-pharmaceuticals-presents-new-data-on-vp-315-from-its-phase-2-clinical-trial-in-basal-cell-carcinoma-at-the-40th-society-for-immunotherapy-of-cancer-annual-meeting/
0 · Reply
phd101
phd101 May. 13 at 5:29 PM
$VRCA strong rev growth
1 · Reply
MarketBeat
MarketBeat May. 13 at 3:09 AM
https://marketbeat.com/a/8651239/ $VRCA Verrica Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript
0 · Reply
BioGem
BioGem May. 12 at 9:29 PM
$VRCA I have mentioned their dismal performance for the past 6 months, and not sure why investors still bought it, all while they diluted by double the number of shares not too long ago. -Adoption of the product in the USA is too weak and slow, despite a big expansion in their sales team. -Their losses are deepening. -Cash burn is too heavy and unsustainable. -Cash is already critically low. -Add several millions in pre-funded warrant already vested. -I expect another round of dilution imminently.
0 · Reply
Merlintrader
Merlintrader May. 12 at 8:21 PM
$VRCA Verrica Pharmaceuticals (Nasdaq: $VRCA): Q1 2026 earnings show stronger YCANTH demand, lower debt burden and a still-tight cash clock https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 8:12 PM
$VRCA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.45 up 55.00% YoY • Reported revenue of $5.02M up 46.06% YoY
0 · Reply
GOLDENSAFEBETS
GOLDENSAFEBETS May. 6 at 10:13 PM
$VRCA 👀
1 · Reply
Merlintrader
Merlintrader May. 5 at 8:39 PM
$VRCA Verrica Pharmaceuticals: VP-315 Phase 2 Data Put a Fresh Spotlight on Basal Cell Carcinoma https://www.merlintrader.com/verrica-pharmaceuticals-may2026-update/
0 · Reply
PatrickandFrankie
PatrickandFrankie Apr. 30 at 12:39 PM
$VRCA whats up ? Any news in premarket?
0 · Reply
Merlintrader
Merlintrader Apr. 13 at 3:36 PM
$VRCA
0 · Reply
Merlintrader
Merlintrader Apr. 10 at 1:34 PM
$VRCA Verrica Pharmaceuticals ( $VRCA): deep dive 2026 after the balance-sheet reset, the YCANTH ramp and the renewed VP-315 scientific story https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/
0 · Reply
focafoca99
focafoca99 Apr. 9 at 9:11 PM
$VRCA said a late-breaking abstract on VP-315 was accepted for SID 2026, with the company highlighting a potential abscopal effect in basal cell carcinoma.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 9 at 2:52 AM
$VRCA
0 · Reply
focafoca99
focafoca99 Apr. 6 at 6:31 PM
$VRCA is just promoting participation in the Needham healthcare conference.
0 · Reply
SkullInferno
SkullInferno Mar. 30 at 6:08 PM
$VRCA
0 · Reply
BioGem
BioGem Mar. 14 at 11:53 PM
$VRCA Shortable above 6$. Including the additional vested pre-funded warrants, they have near 21.5M shares outstanding, and the mkt cap of 130M. Too expensive with many critical negatives: -No growth QOQ of product revenue. Means adoption is poor. Generics and new at-home options are ruthless competition. -Deep operating and bottom-line losses to deepen through 2026 (expansion of sales and marketing and launching new trials). -Much lower accounts receivable and higher current liabilities now, mean a big cash burn in Q1 26. -Cash will run out before year end = Another very dilutive offering will be required.
1 · Reply
prismmarketview
prismmarketview Mar. 12 at 1:33 PM
We've added Verrica Pharmaceuticals (NASDAQ: $VRCA) to the PRISM Pharmaceuticals Index, spotlighting its focused work in dermatology and specialty care. YCANTH is gaining solid early commercial traction, with strong 2025 revenue growth reflecting increasing adoption for molluscum contagiosum. The pipeline continues to advance meaningfully: a global Phase 3 program for common warts is underway following the first patient dosing late last year, and VP-315 is progressing in development as a potential non-surgical option for basal cell carcinoma. This addition underscores Verrica's commitment to addressing unmet needs in skin disease treatments. @VerricaPharma #Pharmaceuticals https://prismmarketview.com/companies/verrica-pharmaceuticals-inc/
0 · Reply
mikesterz7
mikesterz7 Mar. 11 at 12:50 PM
$VRCA Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 target price.
0 · Reply